2021
Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion
Perreault S, Schiffer M, Clinchy-Jarmoszko V, Bocchetta N, Barbarotta L, Abdelghany O, Foss F, Huntington S, Seropian S, Isufi I. Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion. American Journal Of Health-System Pharmacy 2021, 78: 1112-1117. PMID: 33617630, PMCID: PMC7929449, DOI: 10.1093/ajhp/zxab072.Peer-Reviewed Original ResearchConceptsHome-based infusionsCOVID-19 exposureSCIG infusionsIntravenous immune globulin therapyBetter patient understandingImmune globulin infusionImmune globulin therapyPatient Outcome QuestionnairePatient outcome assessmentInfusion-related complicationsChair timeRisk of infectionCoronavirus disease 2019 (COVID-19) virusGlobulin therapyIVIG infusionIVIG therapyChart reviewImmunosuppressed populationImmunosuppressed patientsInfusion visitsMedical visitsOutcomes QuestionnairePatient satisfactionPatient understandingInfusion clinic
2020
577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose ≥ 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid Therapy
Perreault S, Schiffer M, Zhao J, McManus D, Foss F, Gowda L, Isufi I, Seropian S, Topal J. 577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose ≥ 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid Therapy. Open Forum Infectious Diseases 2020, 7: s353-s354. PMCID: PMC7776791, DOI: 10.1093/ofid/ofaa439.771.Peer-Reviewed Original ResearchSurveillance blood culturesBlood culturesGVHD patientsSteroid therapyDay mortalitySurveillance culturesPositive culturesHematopoietic stem cell transplant patientsGraft Versus Host DiseaseStem cell transplant patientsBlood culture positivity rateYale-New Haven HospitalSymptoms of GVHDVersus Host DiseaseCell transplant patientsNumber of patientsLack of symptomsCulture positivity rateDiagnosis of infectionNew Haven HospitalRisk of infectionCoagulase-negative staphylococciActive GVHDHost diseaseMedian dose
2013
Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides
Lloyd S, Chen Z, Foss FM, Girardi M, Wilson LD. Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides. Journal Of The American Academy Of Dermatology 2013, 69: 537-543. PMID: 23849563, DOI: 10.1016/j.jaad.2013.04.063.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultAge FactorsAgedAnalysis of VarianceCohort StudiesDermatomycosesDose Fractionation, RadiationDose-Response Relationship, RadiationElectronsFemaleHumansIncidenceMaleMiddle AgedMultivariate AnalysisMycosis FungoidesNeoplasm InvasivenessNeoplasm StagingPrognosisRadiodermatitisRadiotherapy DosageRetrospective StudiesRisk AssessmentSeverity of Illness IndexSex FactorsSkin Diseases, BacterialSkin NeoplasmsWhole-Body IrradiationConceptsTotal skin electron beam therapyMycosis fungoidesSkin infectionsElectron beam therapyAcute toxicityBeam therapyAcute treatment toxicityRetrospective study designIncidence of infectionRisk of infectionCommon toxicitiesTreatment toxicityCutaneous infectionsSkin painBaseline incidenceToxicity gradeGrade 3Modern seriesGrade 2Grade 1Consecutive coursesFungoidesInfectionStudy designGrade 4